You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 269 No. 10, March 10, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communication
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Sigmoidoscopic Screening in the 1990s

David F. Ransohoff, MD; Christopher A. Lang, MD

JAMA. 1993;269(10):1278-1281.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

COLORECTAL cancer (CRC) is a major cause of morbidity and mortality, accounting for 140000 new cases and 60 000 deaths per year in the United States.1 At present, the most promising strategy to reduce this burden is some form of periodic screening. The goal of screening is early detection of surgically curable cancers, as well as their likely precursors, adenomatous polyps; both may be present for years before disseminated, incurable cancer develops.

Sigmoidoscopic screening at intervals of 3 to 5 years has been widely recommended2-5 because sigmoidoscopy has high sensitivity for detecting early cancers and adenomas. However, routine sigmoidoscopic screening is controversial6-8 because there is no direct evidence from a ramdomized controlled trial to show that screening reduces CRC mortality. Also, the effort involved in applying sigmoidoscopic screening is very large. Thus, despite long-standing recommendations, sigmoidoscopic screening is performed in less than 5% to 10% of eligible . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill (Dr Ransohoff), and the Department of Medicine, University of Colorado, and Colorado Permanente Medical Group, Denver (Dr Lang).


Footnotes

Reprint requests to CB 7105, Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7105 (Dr Ransohoff).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.